HC Wainwright set a $9.00 price target on OpGen (NASDAQ:OPGN) in a research report released on Friday morning. The brokerage currently has a buy rating on the medical research company’s stock.
Other equities research analysts have also issued research reports about the stock. Zacks Investment Research raised shares of OpGen from a hold rating to a buy rating and set a $2.25 price objective for the company in a research report on Thursday, February 15th. ValuEngine raised shares of OpGen from a strong sell rating to a sell rating in a research report on Friday, February 2nd.
Shares of OpGen stock opened at $2.32 on Friday. OpGen has a 52-week low of $1.78 and a 52-week high of $31.25. The stock has a market cap of $11.41, a price-to-earnings ratio of -0.20 and a beta of 1.21. The company has a quick ratio of 1.13, a current ratio of 1.23 and a debt-to-equity ratio of 0.03.
A hedge fund recently raised its stake in OpGen stock. Vanguard Group Inc. increased its position in OpGen Inc (NASDAQ:OPGN) by 1.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 342,860 shares of the medical research company’s stock after purchasing an additional 5,500 shares during the quarter. Vanguard Group Inc. owned 1.25% of OpGen worth $219,000 as of its most recent filing with the Securities and Exchange Commission.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/03/19/hc-wainwright-analysts-give-opgen-opgn-a-9-00-price-target.html.
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.